Skip to main content

Choose a treatment that fits your life.

When it comes to treating a rare bleeding disorder, you have a therapy choice that could fit your lifestyle.

NovoSeven® RT comes in four different vial sizes and can be redosed every two hoursa—so you can get fast bleed control when you need it.

aPatients with Hemophilia A or B with inhibitors, acquired hemophilia or Glanzmann’s thrombasthenia with resistance to platelets can redose every 2 hours. Patients with factor VII deficiency can redose every 4-6 hours.  


Here are some other things to think about when choosing a treatment:

Is it quick to mix and fast to infuse?
Is it room-temperature stable?
How does treatment work when I’m on the go?
Is the packaging small enough to take with me?

Why NovoSeven® RT?

NovoSeven® RT helps the broadest range of patients with bleeding disorders. 
 

Checkmark icon


Experience you can trust:

More than 30 years of experience helping people with rare bleeding disorders treat bleeds.b

Checkmark icon


First rFVIIa approved for:

Hemophilia A or B with inhibitors

Checkmark icon


Only rFVIIa approved for:

  • All ages (children, adolescents, and adults)c
  • Before, during, and after surgery
  • Glanzmann’s thrombasthenia with resistance to platelets, factor VII deficiency, and acquired hemophilia 

bFor people with hemophilia A or B with inhibitors.
cIn people with acquired hemophilia, NovoSeven® RT is only indicated for adults.

How does NovoSeven® RT fit your lifestyle?

Feature comparison chart between NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) and SEVENFACT

dFor people with hemophilia A or B with inhibitors.
eIn people with acquired hemophilia, NovoSeven® RT is only indicated for adults.

Feature comparison chart between NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) and FEIBA

fFEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors.
gIn patients with hemophilia A or B with inhibitors.
hIndividual doses for a joint bleed are compared and based on an 88-kg (194-lb) person.
iPatients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight per minute. All information from FEIBA Package Insert.
jRedosing time does not correlate to body weight.
kRedosing time is based on maximum daily dose and the type of bleed.

MixPro

Quick to mix.

The MixPro® syringe means no extra steps to fill a syringe with diluent.

Ready-to-travel case

Travel-ready, to go where you go.

Get a Ready-to-Travel Case to make storing supplies at home or on the go more convenient.
 

To order a travel case please contact a Novo Nordisk Hemophilia Community Liaison (HCL).

NovoSeven package

It’s easy to get started with NovoSeven® RT.

Once you and your health care provider decide that NovoSeven® RT is right for you, we’re here to help you successfully start your treatment.

 

Justin and Bob have hemophilia A with inhibitors

Hear from people who understand your experience.

Watch our videos to hear people with bleeding disorders talk about traveling and infusing on the go with NovoSeven® RT.

 

Interested in trying NovoSeven® RT?

You may be eligible to try it for free.l To learn more about our trial prescription program, please call 1-844-668-6732 to speak with a NovoSecure™ Specialist.

NovoSeven® RT

lPatients who have been prescribed a Novo Nordisk hemophilia and rare bleeding disorder product for an FDA-approved indication, and who have commercial insurance, may be eligible to receive a limited supply of free product. Patient is not eligible if he/she participates in or seeks reimbursement or submits a claim for reimbursement to any federal or state healthcare program with prescription drug coverage, such as Medicaid, Medicare, Medigap, VA, DOD, TRICARE, or any similar federal or state health care program. Product is provided at no cost to the patient or the HCP, is not contingent on any product purchase, and the patient and HCP must not: (1) bill any third party for the free product, or (2) resell the free product.

Selected Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

What is NovoSeven® RT?

NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
  • You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

What should I tell my healthcare provider before using NovoSeven® RT?

  • Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
    • congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
    • are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
    • history of heart or blood vessel diseases
  • Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven® RT?

  • The most common and serious side effects are blood clots
  • Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please click here for Prescribing Information